Skip to content

EyePoint, Inc. EYPT Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Merck & Co. logo
Merck & Co.MRK
-$460.25M+20.9%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-$8.44M-64.1%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$4.56M+93.5%
HRO
HarrowHROW
-$1.2M+36.5%
Theravance Biopharma logo
Theravance BiopharmaTBPH
-$4.87M-221%
LQD
Liquidia CorporationLQDA
$14.53M+402%

Other financials

Income statement

See full
Revenue$696.0K-97.2%
Gross profit$9.8M-30.1%
Operating income-$87.2M-78.6%
Net income-$84.8M-87.7%
EPS (diluted)-$0.99-52.3%

Balance sheet

See full
Cash & equivalents$77.7M-8.7%
Total debt$22.3M-7.3%
Total equity$230.5M-22.8%
Total assets$288.2M-20.5%

Cash flow

See full
Operating cash flow-$80.5M-51.6%
CapEx$997.0K+261%
Free cash flow-$81.5M-52.7%

Valuation

See full
Market cap$1.21B+108%
Enterprise value$1.15B+122%
P/S158.5×+148×

Profitability

See full
Operating margin-3,700.9%-4,042pp
Net margin-3,566.6%-3,874pp
FCF margin-3,565.9%-3,884pp

Returns & leverage

See full
Return on equity-102.7%+1,157pp
Debt / equity0.1×0.0×
Current ratio6.7×-1.2×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: EyePoint, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about EyePoint, Inc. 's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is EyePoint, Inc. 's change in accrued liabilities?
EyePoint, Inc. (EYPT) reported change in accrued liabilities of $571K in Q1 2026.
How has EyePoint, Inc. 's change in accrued liabilities changed year-over-year?
EyePoint, Inc. 's change in accrued liabilities decreased by 88.5% year-over-year, from $4.97M to $571K.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.